Introduction 24
To prevent mother-to-child transmission of HIV around the delivery, a single-dose 25 administration of nevirapine (sdNVP) administered at start of labour is the most common 26 antiretroviral regimen used in resource-limited settings, as recommended by the World Health 27
Organization in the antiretroviral drugs for treating pregnant women and preventing HIV 28 infection in infants report (http://www.who.int/hiv/pub/guidelines/pmtctguidelines3.pdf). 29
However, the use of sdNVP results in resistance mutations in 15 to 70% of women, at 4 to 6 30 weeks postpartum, compromising the success of subsequent treatments with NVP in mother 31 and child (7, 9) . A recent clinical study suggests that adding a single dose of TDF and FTC at 32 delivery may reduce those resistances by half (6) . 33
Emtricitabine is a potent, once daily (QD) nucleoside reverse transcriptase inhibitor approved 34 for the treatment of human immunodeficiency virus (HIV) in adults and children older than 3 35 months in combination with other antiretroviral agents. The physiological changes associated 36 with pregnancy can lead to significant variations in pharmacokinetics (10, 12, 14) . However, 37 few pharmacokinetic data on emtricitabine in pregnant women (3) and no data on placental 38 transfer are available. Only one study reports pharmacokinetic of emtricitabine in neonates 39 exposed to HIV in utero; apparent elimination clearance was 13 mL/min in 5 to 21 days-old 40 neonates and 22 mL/min in 23 to 42 days-old neonates (5) . This suggests that the youngest 41 neonates have the lowest elimination clearance. The neonatal pharmacokinetics just after birth 42 is still unknown. 43
In the present work, a population pharmacokinetic study was performed on mother, cord and 44 neonatal plasma samples in order i) to describe the concentration-time courses of FTC in 45 mothers, the transfer of FTC from maternal plasma to cord plasma and the neonatal 46 elimination, ii) to study the influence of covariates (such maternal bodyweight, gestational 47 (Fig 1) . Parameters of the model were the absorption rate constant (k a ), maternal elimination 98 clearance from the central compartment (CL), volume of the central maternal compartment 99 (V 1 ), maternal intercompartmental clearance (Q 2 ), volume of the peripheral maternal 100 compartment (V 2 ), maternal to fetal rate constant (k 1F ), fetal to maternal rate constant (k F1 ) 101 and neonate elimination rate constant (k FO ). Since emtricitabine was orally administered, only 102 k a , CL/F, V 1 /F, Q 2 /F, V 2 /F, k 1F , k F1 and k FO were identifiable, where F is the unknown 103 bioavailability. Analytical equations were used in a $PRED section in NONMEM to estimate 104 these pharmacokinetic parameters. When FTC concentrations were below the LOQ, we set 105 them to half of the LOQ. Several error models were investigated (i.e. multiplicative and 106 additive error models) to describe residual variability. Exponential model was used for inter-107 subject variability (ISV). Only significant ISVs on pharmacokinetic were kept. The effect of 108
each patient covariate was systematically tested via generalized additive modeling on the 109 basic model. Continuous covariates (CO), as bodyweight, gestational age, creatinine, height 110
and body surface area were tested according to the following equation, using CL for example, 111
, where θ CL is the typical value of clearance for a patient with 112 the median covariate value and CL CO β is the estimated influential factor for the continuous 113 covariate. When a covariate was missing, it was set to the median value from all the other 114 women. Categorical covariates (CA =0 or 1) were tested according to 115
for inhibitory 116 effect. The type of delivery (TD) was tested according to
where DEL = 1 before delivery and DEL = 0 after delivery. A covariate was kept if its effect 118 was biologically plausible; it produced a minimum reduction of 6.63 in the objective function 119 value (OFV) and a reduction in the variability of the pharmacokinetic parameter, assessed by 120 the associated inter-subject variability. After the 400 mg administration to each pregnant woman, FTC minimal (C min ) and maximal 144 (C max ) plasma concentration and area under the concentration curve (AUC) were derived from 145 the estimated individual pharmacokinetic parameters. Median values and ranges werecalculated and compared to data from adults, in literature. At delivery cord (i.e. fetal) and 147 maternal plasma concentrations were determined. The ratio between fetal and maternal 148 concentrations was calculated and its variation as a function of the delay between drug uptake 149 and delivery was followed. In order to better evaluate placental transfer, for a 400 mg dose 150 administered to the mother, maternal and neonatal areas under the curve were estimated and 151 the ratio between neonatal and maternal AUC was calculated. 152
153
Determination of the optimal dosing scheme for the newborn. 154
The optimal timing for FTC administration to the newborns was determined in order to obtain 155 a similar exposure to that observed in adults, (i. 
Results

172
Demographic data 173
Data from the 38 enrolled women and 32 of their neonates were available for FTC 174 pharmacokinetic evaluation. Table 1 summarizes patients' characteristics. 175
176
Population pharmacokinetics 177
A total of 411 maternal, 37 cord blood concentrations and 66 neonatal concentrations were 178 used for pharmacokinetic analysis. Four maternal residual FTC concentrations were excluded 179 because they were seven to 20 times higher than the three other residual concentrations in the 180 same patient. Seven FTC concentrations were lower than the LOQ, so they were set to half of 181 the LOQ (1). The available data were not sufficient to estimate inter-subject variability for 182 V 1 /F, Q 2 /F, V 2 /F, k 1F and k F1 and fixing the variance of these random effects to zero had no 183 influence on the objective function values (OFV). Variabilities were thus estimated: for k a , 184 CL/F and k FO . All residual variabilities were best described by a proportional error model. 185
The addition of a correlation between mother and cord residual variabilities, using a L2 item, 186 (r= 0.80 (24%)) decreased OFV by 11.8 units. The effects of maternal bodyweight, serum 187 creatinine, gestational age and type of delivery were tested on CL/F and the effects of 188 neonatal bodyweight, height, body surface area and gestational age were tested on k FO , none 189 of these effects was significant. 190 As shown in table 3, despite a higher elimination clearance in pregnant women than in non 258 pregnant adults, the 400 mg emtricitabine administration before delivery produces higher 259 exposure than the 200 mg administration in others adults at steady state. Calculating 260 emtricitabine clearance as a dose to AUC ratio, we found 28.0 L/h for pregnant women (our 261 study) compared to 18.7 L/h (4, 18) and 20.4 L/h for adults (15) . FTC clearance was increased 262 by 37 or 50 %. FTC is primarily excreted by the kidney by both glomerular filtration and 263 tubular secretion with 86% recovery of the dose achieved in urine, as described in the full 264 prescribing information for Truvada ® (http://www.gilead.com/pdf/truvada_pi.pdf). During 265 pregnancy, renal plasma flow increases by 25 to 50% and glomerular filtration rate by 50% 266 which should have enhanced emtricitabine elimination (13) . The lowest FTC clearance 267 increase in the PATCG/IMPAACT P1026 study (23.3 vs 28.0 L/h in our study) may be due 268 the sampling time during pregnancy (third trimester vs the day of delivery in our study). None 269 of the covariates tested had an effect on maternal absorption or elimination clearance.
No data were reported on emtricitabine placental transfer. In this study, from one sample at 271 delivery (at various times after drug administration) in each mother -cord pairs, we could 272 draw maternal and cord concentrations curves as a function of the delay and estimate inter 273 subject and residual variabilities. Placental transfer was estimated as fetal to maternal 274 exposure ratio to the drug. We found a relatively constant ratio of 80% for a delivery 275 occurring at least 4 hours after maternal drug administration. This transfer seems to be mainly 276 (4, 15, 18 ).
As the model was validated thanks to the visual predictive check method, it was used 295 to simulate the optimal dosage. For this, it was assumed that the child had the same absorption 296 rate and bioavailability as the mother and its volume of distribution was proportional to the 297 total maternal volume distribution on a bodyweight basis. Accordingly, in our model, the 298 mean volume of distribution was 16.9 L for a children weighting 2.7 kg at birth, which is 299 close to the volume of distribution of 14 L (t 1/2 =12.5 h and CL=13mL/min) found in the 18 300 children from 0 to 21 days of Blum's study (5) . Moreover, even with a 100% error on 301 neonatal volume of distribution, the AUC 0-24h and the time during which the concentration 302 was above 0.077 mg/L showed a less than 20% change. The optimal single neonatal dose was 303 determined in order to obtain an exposure in neonates similar to the known exposure in adults 304 would have been more appropriate to follow the pharmacologically active part of FTC. It was 308 also supposed that the enzymes of phosphorylation were matures in the neonates (16) . For 309 practical reasons, we suggest that FTC should be administered to the neonate at the same time 310 as tenofovir (unpublished data). As previously shown, tenofovir should be administered 311 quickly after birth, i.e. one hour after delivery, so we simulated concentrations obtained with 312 1, 2 or 3 mg/kg of emtricitabine given one hour after birth to the neonate. A 2 mg/kg FTC 313 dose given 12 hours after birth was also simulated. Taking into account the high exposure of 314 the fetus to the drug due to maternal administration (AUC 0-24h =8.2 mg/L.h), only 1 mg/kg of 315 emtricitabine was needed one hour after birth to reach an AUC 0-24h of 10.1 mg/L.h. However 316 if the neonate could only be administered FTC 12 hours after birth, the dose would increase to 317
In conclusion, the maternal 400 mg emtricitabine administration before delivery 320 produces higher exposure than the 200 mg administration in others adults at steady state. 
